Capital Management Corp Exelixis, Inc. Transaction History

Capital Management Corp

$526 Million
Q2 2025

A detailed history of Capital Management Corp transactions in Exelixis, Inc. stock. As of the latest transaction made, Capital Management Corp holds 183,300 shares of EXEL stock, worth $6.91 Million. This represents 1.54% of its overall portfolio holdings.

Number of Shares

183,300

Previous 259,610 29.39%

Holding current value

$6.91 Million

Previous $9.58 Million 15.7%

% of portfolio

1.54%

Previous 1.93%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Jul 28, 2025	SELL	$34.13 - $46.26 $2.6 Million - $3.53 Million	-76,310 Reduced 29.39%	183,300 $8.08 Million
Q1 2025 May 05, 2025	SELL	$32.38 - $39.16 $2.41 Million - $2.91 Million	-74,435 Reduced 22.28%	259,610 $9.58 Million
Q4 2024 Feb 07, 2025	SELL	$25.39 - $36.46 $792,802 - $1.14 Million	-31,225 Reduced 8.55%	334,045 $11.1 Million
Q3 2024 Oct 30, 2024	BUY	$21.96 - $27.6 $556,686 - $699,660	25,350 Added 7.46%	365,270 $9.48 Million
Q2 2024 Jul 25, 2024	SELL	$20.34 - $23.73 $2.44 Million - $2.84 Million	-119,860 Reduced 26.07%	339,920 $7.64 Million
Q1 2024 May 10, 2024	BUY	$20.17 - $23.93 $1.38 Million - $1.63 Million	68,185 Added 17.41%	459,780 $10.9 Million
Q4 2023 Feb 01, 2024	BUY	$19.25 - $24.13 $518,036 - $649,362	26,911 Added 7.38%	391,595 $9.39 Million
Q3 2023 Oct 30, 2023	BUY	$19.04 - $22.74 $25,323 - $30,244	1,330 Added 0.37%	364,684 $7.97 Million
Q2 2023 Jul 27, 2023	BUY	$18.17 - $20.48 $173,323 - $195,358	9,539 Added 2.7%	363,354 $6.94 Million
Q1 2023 May 08, 2023	SELL	$16.3 - $19.41 $1.28 Million - $1.53 Million	-78,573 Reduced 18.17%	353,815 $6.87 Million
Q4 2022 Jan 24, 2023	SELL	$14.96 - $17.39 $1.14 Million - $1.32 Million	-76,105 Reduced 14.97%	432,388 $0
Q3 2022 Oct 31, 2022	SELL	$15.68 - $22.27 $605,483 - $859,956	-38,615 Reduced 7.06%	508,493 $7.97 Million
Q2 2022 Jul 25, 2022	BUY	$17.44 - $23.16 $1.71 Million - $2.27 Million	97,900 Added 21.79%	547,108 $11.4 Million
Q1 2022 May 03, 2022	BUY	$17.03 - $22.67 $199,676 - $265,805	11,725 Added 2.68%	449,208 $10.2 Million
Q4 2021 Feb 08, 2022	SELL	$15.84 - $21.88 $2.09 Million - $2.88 Million	-131,800 Reduced 23.15%	437,483 $8 Million
Q3 2021 Oct 25, 2021	BUY	$16.3 - $21.14 $2.62 Million - $3.4 Million	160,800 Added 39.37%	569,283 $12 Million
Q2 2021 Jul 30, 2021	BUY	$17.95 - $25.56 $1.74 Million - $2.47 Million	96,823 Added 31.07%	408,483 $7.44 Million
Q1 2021 Apr 26, 2021	BUY	$20.53 - $25.22 $905,455 - $1.11 Million	44,104 Added 16.48%	311,660 $7.04 Million
Q4 2020 Feb 04, 2021	BUY	$18.39 - $24.8 $2.47 Million - $3.33 Million	134,266 Added 100.73%	267,556 $5.37 Million
Q3 2020 Oct 27, 2020	BUY	$20.67 - $26.94 $1.15 Million - $1.5 Million	55,725 Added 71.84%	133,290 $3.26 Million
Q2 2020 Jul 29, 2020	SELL	$16.46 - $27.42 $1.75 Million - $2.92 Million	-106,330 Reduced 57.82%	77,565 $1.84 Million
Q1 2020 May 05, 2020	SELL	$14.46 - $21.8 $693,863 - $1.05 Million	-47,985 Reduced 20.69%	183,895 $3.17 Million
Q4 2019 Feb 03, 2020	BUY	$15.15 - $18.89 $467,907 - $583,417	30,885 Added 15.37%	231,880 $4.09 Million
Q3 2019 Oct 30, 2019	SELL	$17.68 - $22.65 $651,684 - $834,879	-36,860 Reduced 15.5%	200,995 $3.56 Million
Q2 2019 Jul 31, 2019	SELL	$18.93 - $24.75 $407,752 - $533,115	-21,540 Reduced 8.3%	237,855 $5.08 Million
Q1 2019 Apr 25, 2019	SELL	$19.6 - $24.76 $1.69 Million - $2.13 Million	-86,180 Reduced 24.94%	259,395 $6.17 Million
Q4 2018 Jan 29, 2019	BUY	$13.65 - $21.8 $819,000 - $1.31 Million	60,000 Added 21.01%	345,575 $6.8 Million
Q3 2018 Oct 31, 2018	BUY	$15.87 - $22.4 $4.53 Million - $6.4 Million	285,575 New	285,575 $5.06 Million

Others Institutions Holding EXEL

# of Institutions

658

Shares Held

255M

Call Options Held

1.67M

Put Options Held

733K

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $12.1B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Management Corp , based on Form 13F filings with the SEC.

News

Stay updated on Capital Management Corp with notifications on news.

Account

Capital Management Corp Exelixis, Inc. Transaction History